Home Tags Rovalpituzumab Tesirine

Tag: Rovalpituzumab Tesirine

AbbVie Discontinues Research and Development Program for Rovalpituzumab Tesirine

MERU, a Phase III trial evaluating rovalpituzumab tesirine (Rova-T / SC16LD6.5; AbbVie) as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated...

Independent Data Monitoring Committee Recommends Enrollment to be Stopped for Study...

An Independent Data Monitoring Committee (IDMC) responsible for ongoing review of study data of the TAHOE study, a Phase III study evaluating Rovalpituzumab Tesirine...

Researchers Find SCLC-biopsy Specimen Reliable for Evaluating DLL3 Expression

High levels of delta-like protein 3 or DLL3 in small-cell lung cancer or SCLC are correlated with poor survival trends.  Li-Xu Yan, MD, a...

First Patient with Advanced Solid Tumors with HER2 Expression Dosed in...

A first patient with advanced solid tumors with HER2 Expression was dosed in a phase I clinical trial with ADCT-502. The investigational drug being...

What to Expect at the 17th World Conference on Lung Cancer

An estimated 225,000 Americans are expected to be diagnosed with lung cancer this year. Recurrent Small Cell Lung Cancer or accounts for 10%...

Rovalpituzumab tesirine: Most Promising Clinical Candidate

Rovalpituzumab tesirine, also known as Rova-T, an antibody-drug conjugate being developed by AbbVie/Stemcentrx was recognized at the 7th Annual World Antibody Drug Conjugate (ADC)...

Collaboration to Explore the Safety and Efficacy of Combining Rova-T +...

A new Phase I/II clinical program in which Bristol-Myers Squibb collaborates with AbbVie will evaluate the safety, tolerability and efficacy of the investigational biomarker-specific...

Bio International: Innovation Driving Growth in the Biopharmaceutical Market

With our increasing understanding of disease mechanisms and our ability to unlock the power of the immune system to break significant barriers and change...

Rovalpituzumab Tesirine Shows Early Promise in Small Cell Lung Cancer

Rovalpituzumab tesirine (Rova-T or SC16LD6.5; AbbVie), a novel biomarker-specific 'smart-bomb' antibody-drug conjugate or ADC targeting the delta-like protein 3 or DLL3 protein, expressed in more...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

AbbVie Demonstrates Progress in Oncology Research at ASCO 2016

Chemotherapy remains the standard of care in the treatment of many types of cancer. However, one of the problems with chemotherapeutics is that it...